Uruguay’s biotechnology sector is showing signs of significant growth, according to a Mar. 17 study commissioned by Uruguay XXI, the National Agency for Research and Innovation (ANII), and the Inter-American Development Bank (IDB). The report, titled “Biotechnology Companies in Uruguay: Productive, Technological, and Economic Characteristics of a Growing Industry,” provides the first systematic mapping of the country’s biotech industry.
The study matters because it offers data-driven insights into an emerging ecosystem that is attracting increasing interest from investors. With 62 active biotechnology companies identified—62% of which are startups—the sector has expanded rapidly over the past decade. Between 2014 and 2025, 45 new biotech firms were created, with most being startups. This trend points to a dynamic environment where science-based ventures are taking root, many originating from Uruguay’s research system.
The report found that Montevideo and Canelones host 85% of these companies, benefiting from proximity to universities, research centers, scientific infrastructure, and specialized talent. The workforce is highly skilled: overall, 44% hold university degrees and 11% have PhDs; among startups specifically, those numbers rise to 62% with degrees and 31% with doctorates.
Innovation is another key feature of Uruguay’s biotech landscape. In 2024 alone, companies allocated two-thirds of their innovation spending to research and development. Seventy percent introduced new products between 2022 and 2024; one-third developed innovations new to global markets. Financially, surveyed firms reported total sales of $34.9 million U.S., with exports reaching $28.7 million U.S., resulting in a positive trade balance for biotechnology.
Cristina Montero, Life Sciences Investment Specialist at Uruguay XXI, said having an up-to-date profile of the sector “is very important” for positioning Uruguay among potential investors. She described biotechnology as “highly capital-intensive,” requiring ongoing investment to move from research through commercialization while offering “enormous potential for impact” in healthcare, food production, and sustainability.
The study concludes that Uruguay is becoming a hub where stability, talent availability, scientific capabilities, and support for entrepreneurship converge—factors valued by both established firms and startups seeking locations for growth.
